The eukaryotic translation initiation factor eIF4E reprograms alternative splicing
The EMBO Journal · 2023
DOI: 10.15252/embj.2021110496 ↗Kurz gefasst
Fachartikel in der Zeitschrift The EMBO Journal, 2023. Verfasst von Mehdi Ghram und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Cell Biology, Institute for Research in Immunology and Cancer, University of Montreal, Montreal, QC, Canada. Hauptthemen laut MEDLINE: Alternative Splicing, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, National Institutes of Health, Leukemia and Lymphoma Society.
Abstract (Originalsprache)
Aberrant splicing is typically attributed to splice‐factor (SF) mutation and contributes to malignancies including acute myeloid leukemia (AML). Here, we discovered a mutation‐independent means to extensively reprogram alternative splicing (AS). We showed that the dysregulated expression of eukaryotic translation initiation factor eIF4E elevated selective splice‐factor production, thereby impacting multiple spliceosome complexes, including factors mutated in AML such as SF3B1 and U2AF1. These changes generated a splicing landscape that predominantly supported altered splice‐site selection for ~800 transcripts in cell lines and ~4,600 transcripts in specimens from high‐eIF4E AML patients otherwise harboring no known SF mutations. Nuclear RNA immunoprecipitations, export assays, polysome analyses, and mutational studies together revealed that eIF4E primarily increased SF production via its nuclear RNA export activity. By contrast, eIF4E dysregulation did not induce known SF mutations or alter spliceosome number. eIF4E interacted with the spliceosome and some pre‐mRNAs, suggesting its direct involvement in specific splicing events. eIF4E induced simultaneous effects on numerous SF proteins, resulting in a much larger range of splicing alterations than in the case of mutation or dysregulation of individual SFs and providing a novel paradigm for splicing control and dysregulation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology and Cell Biology, Institute for Research in Immunology and Cancer, University of Montreal, Montreal, QC, Canada.
- Institute for Research in Immunology and Cancer (IRIC), Université de Montréal, Montreal, QC, Canada.
- Department of Physiology and Biophysics, Institute for Computational Biomedicine, Weill Cornell Medicine, New York, NY, USA.
- Applied Bioinformatics Core, Weill Cornell Medicine, New York, NY, USA.
- Division of Hematology/Oncology, Department of Medicine, Weill Cornell Medicine, Cornell University, New York, NY, USA.
ORCID-Profile: Mehdi Ghram, Gavin Morris, Biljana Culjkovic-Kraljacic, Jean-Clement Mars, Patrick Gendron, Maria Victoria Revuelta, Leandro Cerchietti, Katherine L B Borden
Förderung
- NCI NIH HHS
- National Institutes of Health
- Leukemia and Lymphoma Society
Zitieren
APA
Ghram, M., Morris, G., Culjkovic-Kraljacic, B., Mars, J. C., Gendron, P., Skrabanek, L., Revuelta, M. V., Cerchietti, L., Guzman, M. L., & Borden, K. L. B. (2023). The eukaryotic translation initiation factor eIF4E reprograms alternative splicing. The EMBO Journal. https://doi.org/10.15252/embj.2021110496
Vancouver
Ghram M, Morris G, Culjkovic-Kraljacic B, Mars JC, Gendron P, Skrabanek L, et al. The eukaryotic translation initiation factor eIF4E reprograms alternative splicing. The EMBO Journal. 2023. doi:10.15252/embj.2021110496
BibTeX
@article{Ghram2023,
author = {Ghram, Mehdi and Morris, Gavin and Culjkovic-Kraljacic, Biljana and Mars, Jean-Clement and Gendron, Patrick and Skrabanek, Lucy and Revuelta, Maria Victoria and Cerchietti, Leandro and Guzman, Monica L and Borden, Katherine L B},
title = {The eukaryotic translation initiation factor eIF4E reprograms alternative splicing},
journal = {The EMBO Journal},
year = {2023},
doi = {10.15252/embj.2021110496}
}
EUVIMED